Der Wolkenkratzer Bank of America Plaza in Dallas.
Freitag, 27.01.2017 08:20 von GlobeNewswire | Aufrufe: 76

CellaVision AB: Nomination Committee proposes re-election of Chairman and members to the Board of Directors

Der Wolkenkratzer Bank of America Plaza in Dallas. pixabay.com

This information was released for public disclosure on January 27, 2017 at 08.20 am CET.


CellaVision AB (public) today announced that its Nomination Committee proposes 
re-election of Sören Mellstig as Chairman of the Board and re-election of Christer Fåhraeus, Åsa Hedin, Roger Johanson, Torbjörn Kronander, Anna Malm Bernsten and Niklas Prager as Directors of the Board.


The Nomination Committee consists of the four largest shareholders represented by Nominatoion Committee Chairman Christer Fåhraeus (appointed by Christer Fåhraeus and companies), Bo Lundgren (appointed by Swedbank Robur Funds), Caroline Sjösten (appointed by Skandia Liv), Joel Eklund (appointed by Eklund & Peterson AB) and the Chairman of the Board Sören Mellstig.

The Nomination Committee's proposal for Board members:
Sören Mellstig - Chairman of the Board
Christer Fåhraeus - Board Member
Åsa Hedin - Board Member
Roger Johanson - Board Member
Torbjörn Kronander - Board Member
Anna Malm Bernsten - Board Member
Niklas Prager - Board Member

The Nomination Committee believes that the Board's expertise and experience thus meets the requirements that may arise. The Nomination Committee's other proposals to the Annual General Meeting, that will be held in Lund on CellaVision AB at 15:00 on May 5, will be published in the notice of the Annual General Meeting released to the public on
March 28, 2017.

 

 For more information, please contact:

Christer Fåhraeus, Chairman of the Nomination Committee, CellaVision AB
Tel: +46 (0) 705-60 90 00 | E-mail: cf@flatfrog.com

Sören Mellstig, Chairman of the Board, CellaVision AB
Tel: +46 (0) 70- 513 65 81| E-mail: soren@mellstig.se


ARIVA.DE Börsen-Geflüster

Kurse

18,84
+0,64%
Cellavision Realtime-Chart


About CellaVision

CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the mother company in Lund and by the market support organizations in the US, Canada, China and Japan. In 2015 sales were SEK 239 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Small Cap list. Read more at www.cellavision.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CellaVision AB via Globenewswire

Werbung

Mehr Nachrichten zur Cellavision Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Andere Nutzer interessierten sich auch für folgende News